EU project improves ability to predict outcome of HIV treatment

European and Israeli researchers are working together on the development of a clinical management system for the use of drugs and drug combinations given to HIV patients, as part of an EU-funded project.

The EuResist project, funded under the EU's Sixth Framework Programme (FP6), aims to give clinicians the tools they need to predict what the response will be to antiretroviral treatment among HIV patients.

Nowadays, an HIV infection is no longer a death sentence: the number of approved treatments grows each year. However, according the experts, the virus is becoming resistant to an increasing number of drugs and is developing different strains. In order to ensure the effectiveness of anti-HIV drugs, a combination or 'cocktail' of drugs must be used according to the progress of an individual's virus and as resistance to the drugs change.

"Monitoring the history of treatments and the progress of the virus itself is crucial to successful patient care," says Boaz Carmeli, Manager of Healthcare and Life Science at the IBM Haifa Research Lab, one of the partners in the project. "Tapping into knowledge garnered from a huge collection of data will help doctors take into account the patient, the virus, the viral mutations, and the current stage of the disease."

The project will use an innovative approach to predict the efficiency of anti-retroviral drug regimens, developing a number of prediction engines, including evolutionary models, mutual information-based data mining and case-based reasoning.

Clinicians will then, finally, be able to select the best drugs and cocktails for treating their patients. The consortium will be using EuResist's biomedical information integration technology to collect data from three leading HIV databases in Europe: ARCA of Italy, AREVIR of Germany and that of Sweden's Karolinska Infectious Diseases and Clinical Virology Department.

The data includes treatment histories, treatment response information, and the sequence of the relevant part of the HIV genome (genotype). The resulting EuResist integrated data set is expected to be the largest in the world.

"If we look closely at the current patient's blood work, virus stage, family history, race, and so forth - and then compare it to the thousands of people who have been treated over the years, we can see what was done, what worked, and what didn't," notes Professor Maurizio Zazzi, EuResist scientific coordinator and Professor of Microbiology at the University of Siena School of Medicine.

On the basis of this history data, EuResist can predict how the virus will respond to a certain cocktail. "This method not only provides a huge saving in costs, it also means a patient's chances for successful treatment are not dependant on their doctor's individual knowledge," Professor Zazzi added.

A particularly beneficial aspect of EuResist will be web interaction. A physician is able to input a patient's information and status and then get a summary of what is known about this specific virus stage, along with a prediction of what treatment is likely to help the patient.

The EuResist database currently has access to information from over 17,000 patients and, according to the project partners, the project results so far are showing a tremendous success rate of 75%.

For further information, please visit:
http://www.euresist.org

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Moderna's COVID-19 vaccine candidate meets its pri…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Pfizer and BioNTech conclude Phase 3 study of COV…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based...

Pfizer and BioNTech to submit Emergency Use Author…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authori...

Phase 2 trial of Oxford COVID-19 vaccine in health…

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 ye...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Chinese vaccine candidate based on inactivated SAR…

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published in The Lanc...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...